P2RY12 and chronic kidney disease: In the subgroup analyses, we did not observe significant interaction in the relationship between P2Y12 inhibitors and MOF across different subgroups—age, sex, presence of diabetes, presence of CKD and history of fractures (Table 3 and Fig. 3).